A prospective randomized study of CHOP versus CHOP plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: The International Oncology Study Group NHL1 study

Basit Öğe Kaydı
dc.authoridFerhanoglu, Burhan/0000-0002-4257-549X
dc.authoridSuharti, Catharina/0000-0001-9755-893X
dc.authoridLekhakula, Arnuparp/0000-0002-0196-8107
dc.authorwosidCheong, Soon-Keng/AAM-8357-2021
dc.contributor.authorGiles, FJ
dc.contributor.authorShan, JQ
dc.contributor.authorAdvani, SH
dc.contributor.authorAkan, H
dc.contributor.authorAydogdu, I
dc.contributor.authorAziz, Z
dc.contributor.authorAzim, HA
dc.date.accessioned2024-08-04T20:56:21Z
dc.date.available2024-08-04T20:56:21Z
dc.date.issued2000
dc.departmentİnönü Üniversitesien_US
dc.description.abstractThe addition of a brief alpha interferon regimen to each CHOP induction cycle, plus one year of alpha interferon thrice weekly maintenance therapy, has no early effect on response rates or survival in patients with Intermediate or High grade cell NHL. Background: The CHOP (Cyclophosphamide, Adriamycin, Vincristine, Prednisone) regimen is the most widely used first-line therapy for patients with Intermediate or High Grade (IG/HG) non-Hodgkin's lymphoma (NHL). Alpha 2b interferon (INF) enhances response rates and improves survival in low-grade NHL. The International Oncology Study Group (IOSG) conducted a prospective randomized study comparing CHOP alone or combined with INF in patients with IG/HG-NHL. The primary study aim was to compare the objectiveresponse rates in these patient cohorts. Patients and Methods: Patients with a confirmed diagnosis of measurable NHL of International Working Formulation (IWF) groups D to H histology were randomized to receive CHOP alone or CHOP with 5Mu INF SC for 5 days on days 22 to 26 of each 28 day cycle with INF 5 million units (Mu) given three times per week subcutaneously for 52 weeks in those patients who responded to CHOP plus INF Results: The overall response rates were equivalent in both groups: CHOP alone (214 patients) 81% (complete 55%, partial 26%): CHOP plus INF (221 patients) 80% (complete 54%, partial 26%). At 36 months, the actuarial survival rate was equivalent in both groups. Conclusions: There is no apparent early advantage in terms of response or survival conferred by adding the study INF regimen to CHOP therapy for patients with IG/HC-NHL.en_US
dc.identifier.doi10.3109/10428190009054885
dc.identifier.endpage103en_US
dc.identifier.issn1042-8194
dc.identifier.issn1029-2403
dc.identifier.issue1-2en_US
dc.identifier.pmid11426633en_US
dc.identifier.startpage95en_US
dc.identifier.urihttps://doi.org/10.3109/10428190009054885
dc.identifier.urihttps://hdl.handle.net/11616/102230
dc.identifier.volume40en_US
dc.identifier.wosWOS:000166585600009en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofLeukemia & Lymphomaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectlarge cell lymphomaen_US
dc.subjectcyclophosphamideen_US
dc.subjectvincristineen_US
dc.subjectadriamycinen_US
dc.subjectPrednisoneen_US
dc.subjectinterferonen_US
dc.subjectresponseen_US
dc.subjectsurvivalen_US
dc.subjectCHOPen_US
dc.subjectCHOP+alpha-2b interferonen_US
dc.subjectintermediateen_US
dc.subjecthigh grade lymphomasen_US
dc.subjectnon Hodgkin's lymphomaen_US
dc.subjectInternational Oncology Study Groupen_US
dc.titleA prospective randomized study of CHOP versus CHOP plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: The International Oncology Study Group NHL1 studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu